Noteworthy, accurate cancer screening should be performed in DM patients with anti-transcription intermediary factor 1 (TIF1)-γ autoantibodies, which are associated with a higher risk of underlying malignancies [97,98]. This evidence concerns the gene TRIM24 and dermatomyositis.